Figures & data
Figure 1. (a) Number of phage output in each round of panning. (b) Identification the positive clones binding to Cry2A toxin by phage-ELISA. NC, negative control.
![Figure 1. (a) Number of phage output in each round of panning. (b) Identification the positive clones binding to Cry2A toxin by phage-ELISA. NC, negative control.](/cms/asset/a8662815-e1ec-492c-bd03-697431f342a3/cfai_a_1642307_f0001_oc.jpg)
Figure 2. (a) The amino acid sequences of the positive clones. (b) Result of matching between nanobodies and anti-Cry2A PAb detected by sandwich ELISA. NC, negative control.
![Figure 2. (a) The amino acid sequences of the positive clones. (b) Result of matching between nanobodies and anti-Cry2A PAb detected by sandwich ELISA. NC, negative control.](/cms/asset/ee12603e-84f4-4705-8307-dccffc2225ad/cfai_a_1642307_f0002_oc.jpg)
Figure 3. Optimization of (a) capture antibody (anti-Cry2A PAb) and (b) detection antibody (phage-displayed nanobody P2) concentrations.
![Figure 3. Optimization of (a) capture antibody (anti-Cry2A PAb) and (b) detection antibody (phage-displayed nanobody P2) concentrations.](/cms/asset/812ce87f-9a98-4e54-870e-370ec3fc08b3/cfai_a_1642307_f0003_ob.jpg)
Figure 4. Standard curve of phage-displayed nanobody based DAS-CLIA for Cry2A toxin analysis under the optimized conditions.
![Figure 4. Standard curve of phage-displayed nanobody based DAS-CLIA for Cry2A toxin analysis under the optimized conditions.](/cms/asset/82fa5edd-a7f9-497f-875e-69a9d0183eb4/cfai_a_1642307_f0004_ob.jpg)